share_log

Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving Average of $5.28

Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50 Day Moving Average of $5.28

卡布里科治療公司(納斯達克代碼：CAPR)股價突破50日移動均線5.28美元
Defense World ·  2022/09/28 14:41

Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating)'s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $5.28 and traded as high as $5.88. Capricor Therapeutics shares last traded at $5.79, with a volume of 100,350 shares trading hands.

在週二的交易中，Capricor Treateutics Inc.(納斯達克代碼：CAPR-GET Rating)的股價突破了50日移動均線。該股的50日移動均線為5.28美元，最高交易價格為5.88美元。Capricor Treateutics的股票最新報5.79美元，成交量為100,350股。

Capricor Therapeutics Trading Up 0.5 %

Capricor Treateutics股價上漲0.5%

The stock has a 50 day moving average of $5.28 and a 200-day moving average of $4.31. The company has a market capitalization of $140.96 million, a P/E ratio of -5.57 and a beta of 4.84.

該股的50日移動均線切入位在5.28美元，200日移動均線切入位在4.31美元。該公司市值為1.4096億美元，市盈率為-5.57，貝塔係數為4.84。

Get
到達
Capricor Therapeutics
卡布裏卡治療公司
alerts:
警報：

Capricor Therapeutics (NASDAQ:CAPR – Get Rating) last announced its quarterly earnings data on Wednesday, August 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). During the same quarter in the prior year, the company posted ($0.21) earnings per share. As a group, sell-side analysts expect that Capricor Therapeutics Inc will post -1.17 EPS for the current fiscal year.

卡布里科治療公司(納斯達克代碼：CAPR-GET Rating)上一次公佈季度收益數據是在8月10日星期三。這家生物技術公司公佈的季度每股收益(EPS)為0.29美元，低於分析師普遍預期的0.25美元和0.04美元。去年同期，該公司公佈的每股收益為0.21美元。作為一個集團，賣方分析師預計，Capricor治療公司將公佈本財年每股收益1.17歐元。

Institutional Inflows and Outflows

機構資金流入和流出

A number of large investors have recently added to or reduced their stakes in CAPR. Selective Wealth Management Inc. purchased a new position in Capricor Therapeutics in the 1st quarter worth approximately $732,000. Vanguard Group Inc. lifted its holdings in Capricor Therapeutics by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock worth $3,502,000 after purchasing an additional 54,260 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Capricor Therapeutics by 54.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock worth $510,000 after purchasing an additional 52,611 shares in the last quarter. Bailard Inc. purchased a new position in Capricor Therapeutics in the 2nd quarter worth approximately $104,000. Finally, UBS Group AG lifted its holdings in Capricor Therapeutics by 326.0% in the 2nd quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 22,462 shares in the last quarter. 10.43% of the stock is owned by hedge funds and other institutional investors.
一些大型投資者最近增持或減持了CAPR的股份。選擇性財富管理公司在第一季度購買了Capricor治療公司的一個新頭寸，價值約73.2萬美元。先鋒集團(Vanguard Group Inc.)在第一季度增持了Capricor Treeutics 5.6%的股份。先鋒集團(Vanguard Group Inc.)現在持有這家生物技術公司1,020,998股股票，價值3,502,000美元，該公司在上個季度又購買了54,260股票。Dimension Fund Advisors LP在第一季度增持了Capricor Treateutics 54.7%的股份。Dimension Fund Advisors LP現在擁有這家生物技術公司148,768股股票，價值51萬美元，上個季度又購買了52,611股。Bailard Inc.在第二季度購買了Capricor治療公司的一個新頭寸，價值約10.4萬美元。最後，瑞銀集團在第二季度增持了326.0%的Capricor Treateutics股份。瑞銀集團(UBS Group AG)現在擁有29,352股這家生物技術公司的股票，價值102,000美元，上個季度又購買了22,462股。10.43%的股票由對衝基金和其他機構投資者持有。

Capricor Therapeutics Company Profile

Capricor治療公司簡介

(Get Rating)

(獲取評級)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

卡布里科治療公司(納斯達克代碼：CAPR)是一家臨牀階段的生物技術公司，專注於治療罕見疾病的一流生物療法的發現、開發和商業化。Capricor的主要候選藥物CAP-1002是一種異基因細胞療法，目前正在臨牀開發中，用於治療Duchenne肌營養不良症。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
  • Defensive Stocks For A Volatile Market
  • SunPower Is Ready To Power Up Triple-Digit Earnings Gains
  • Will UPS Be Next to Deliver a Warning?
  • Is This the Darkest Before the Dawn for Gap Stock?
  • Build A Better Tech Portfolio With Jabil Inc.
  • 免費獲取StockNews.com關於Capricor治療(CAPR)的研究報告
  • 防禦性股票應對動盪的市場
  • SunPower準備推動三位數的收益增長
  • UPS會成為下一個發出警告的公司嗎？
  • 這是Gap Stock黎明前最黑暗的一次嗎？
  • 與捷普公司一起打造更好的技術產品組合。

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Capricor Treateutics Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Capricor Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論